As of Aug 18
| +0.04 / +3.39%|
The 1 analysts offering 12-month price forecasts for Pluristem Therapeutics Inc have a median target of 2.00, with a high estimate of 2.00 and a low estimate of 2.00. The median estimate represents a +63.93% increase from the last price of 1.22.
The current consensus among 1 polled investment analysts is to Buy stock in Pluristem Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.